

Bodipy photosensitizer linked hybrid nanomaterials for photodynamic therapy

Feyza Kostak ¹, Omar Kerbouche ², Suray Pehlivanoglu ^{1*}, Seda Demirel Topel ^{2*}

¹Necmettin Erbakan University, Department of Molecular Biology and Genetics, Konya, 42090, Turkey

²Antalya Bilim University, Department of Electrical and Electronics Engineering, Antalya, 07190, Turkey

*E-mail: seda.demireltopel@antalya.edu.tr²; spehlivanoglu@erbakan.edu.tr¹


Presenting Author' Biography



Seda Demirel Topel has received her PhD degree in Organic Chemistry (2013, Akdeniz University, Turkey). In the first years of her PhD, she joined the Natural Products group as a researcher at Lund University, Sweden, then continued her PhD studies at National Nanotechnology Research Center (UNAM), Bilkent University, Turkey in the field of organic-hybrid nanoparticles for photodynamic therapy (2010-2013). Then she continued her studies as a post-Doc fellow at the Department of Molecular Sciences, SLU, Sweden in 2013-2014. Currently, she is working as Assist. Prof. at the Department of Electrical & Electronics

Engineering at Antalya Bilim University, since 2017. Her research interests include the synthesis and characterization of various types of nanoparticles such as silicon dioxide, titanium dioxide, superparamagnetic iron oxide and upconversion nanoparticles and their hybrid forms with organic ligands for biological applications such as theranostics, bio-imaging and controlled drug delivery.

Graphical Abstract



Abstract

Photodynamic therapy (PDT) is an alternative clinically approved treatment method to obliterate the cancerous lesion by producing reactive oxygen species (ROS) via activated a photosensitizer (PS) molecule at a certain wavelength¹. In recent years, Bodipy (4,4-difluoro-4-bora-3a,4a-diaza-s-indacene) as a photosensitizer molecule has been extensively investigated in PDT^{2,3}. However, the use of many Bodipy PS in PDT has been limited due to their insolubility in aqueous solution. Therefore, nanotechnology offer tremendous solutions to build up nano-carrier systems for insoluble molecules. We have herein developed a stable formulation of hybrid Bodipy PS via conjugation of TiO₂ nanoparticles to the Bodipy PS. In this study, a heavy metal substituted Bodipy PS molecule has been synthesized and linked to polyethyleneimine (PEI) functionalized TiO₂ nanoparticles to increase the stability and biocompatibility of the photosensitizer in physiological conditions (pH:7.4) as a potential photodynamic therapy agent. PEI-TiO₂ nanoparticles have been prepared by a hydrothermal method which yields anatase phase crystals with an average diameter of 5 nm. Singlet oxygen studies reveal that the pure Bodipy derivative (BOD 1) has been resulted to 85% decrease in the absorbance of trap molecule, DPBF (diphenyl benzoisofuran), in 180 seconds under 532 nm LED light. Furthermore, the cytotoxicity for the hybrid photosensitizer has been tested against CRL-4010 and MDA-MB-231 cancer cell lines under UV light exposure at a certain time. BOD1-TiO₂ nanoparticles have been found to be effective on both cell lines. IC₅₀ value has been calculated as 0.16 ppm and 0.23 ppm for pure BOD 1 on CRL-4010 and MDA-MB-231 cells, respectively, after 5 minutes LED light irradiation. However, IC₅₀ values have been raised to 115.60 and 99.53 ppm on CRL-4010 and MDA-MB-231 cell lines, respectively, when BOD1 was functionalized with PEI-TiO₂ nanoparticles. Colony forming experiments show that BOD1 at a concentration of 1 ppm in DMSO has been completely inhibited the colony formation for both cancer cell lines. When BOD1 conjugated to TiO₂ nanoparticles, it has been revealed that it has not superior effect like bare BOD1 on colony formation, however exhibited approximately 20 % inhibition for both cancer cells due to the low conjugation effect of BOD1 to TiO₂ nanoparticle. Nevertheless, the resultant BOD1-TiO₂ hybrid formulation has been exhibited a stable dispersion in physiological solution to apply as a singlet oxygen generator for PDT.

Keywords: photodynamic therapy; TiO₂; Bodipy; CRL-4010 cells; MDA-MB-231 cells

Acknowledgements

The authors are acknowledged to Antalya Bilim University and Necmettin Erbakan University for their financial support.

References

1. A.F. Santos, D. R.Q. Almeida, L. F. Terra, M.S. Baptista, L. Labriola, *J. Cancer Metastasis Treat*, **2019**, 5, 25.
2. S. Erbas Cakmak, F.Pir Cakmak, S. Demirel Topel, T.B. Uyar, E. U. Akkaya, *Chem. Commun*, **2015**, 51, 12258.
3. S. Demirel Topel, G. Turgut Cin, E.U. Akkaya, *Chem. Commun*, **2014**, 50, 8896.